Taken together, preclinical models of PD demonstrate the promising neuroprotective potential for GLP-1 receptor agonists to reduce inflammation and α-synuclein accumulation, whilst restoring mitochondrial function and motor deficits. Here, GLP1R is linked to Parkinson disease.